Fred Alger Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.24M | Sell |
298,032
-113,831
| -28% | -$2.56M | 0.03% | 209 |
|
|
2025
Q4 | $9.47M | Sell |
411,863
-36,854
| -8% | -$1.21M | 0.04% | 174 |
|
|
2025
Q3 | $13.5M | Buy |
448,717
+18,378
| +4% | +$551K | 0.05% | 161 |
|
|
2025
Q2 | $15.6M | Sell |
430,339
-94,298
| -18% | -$3.4M | 0.07% | 135 |
|
|
2025
Q1 | $19M | Buy |
524,637
+58,372
| +13% | +$2.43M | 0.11% | 114 |
|
|
2024
Q4 | $19.6M | Sell |
466,265
-70,033
| -13% | -$3.47M | 0.09% | 137 |
|
|
2024
Q3 | $29.8M | Sell |
536,298
-12,607
| -2% | -$642K | 0.14% | 108 |
|
|
2024
Q2 | $22.6M | Sell |
548,905
-32,646
| -6% | -$1.39M | 0.11% | 121 |
|
|
2024
Q1 | $27.2M | Sell |
581,551
-22,425
| -4% | -$1.06M | 0.13% | 125 |
|
|
2023
Q4 | $28.9M | Sell |
603,976
-34,890
| -5% | -$1.35M | 0.16% | 120 |
|
|
2023
Q3 | $22.8M | Sell |
638,866
-17,239
| -3% | -$683K | 0.13% | 137 |
|
|
2023
Q2 | $30.3M | Buy |
656,105
+112,553
| +21% | +$5.22M | 0.15% | 136 |
|
|
2023
Q1 | $21.8M | Buy |
543,552
+48,012
| +10% | +$2.06M | 0.12% | 160 |
|
|
2022
Q4 | $23M | Buy |
495,540
+129,827
| +35% | +$5.11M | 0.12% | 156 |
|
|
2022
Q3 | $15.1M | Buy |
365,713
+103,512
| +39% | +$5.32M | 0.08% | 182 |
|
|
2022
Q2 | $15.6M | Sell |
262,201
-17,572
| -6% | -$1.08M | 0.07% | 184 |
|
|
2022
Q1 | $20.3M | Sell |
279,773
-13,727
| -5% | -$955K | 0.06% | 183 |
|
|
2021
Q4 | $24.7M | Buy |
293,500
+2,577
| +0.9% | +$210K | 0.06% | 194 |
|
|
2021
Q3 | $26.2M | Buy |
290,923
+99,491
| +52% | +$8.99M | 0.06% | 191 |
|
|
2021
Q2 | $18.3M | Buy |
191,432
+16,868
| +10% | +$1.76M | 0.04% | 211 |
|
|
2021
Q1 | $19.9M | Sell |
174,564
-14,709
| -8% | -$2M | 0.05% | 201 |
|
|
2020
Q4 | $26.2M | Sell |
189,273
-70,809
| -27% | -$8.4M | 0.07% | 184 |
|
|
2020
Q3 | $21.4M | Buy |
260,082
+53,761
| +26% | +$4.46M | 0.06% | 161 |
|
|
2020
Q2 | $16.1M | Sell |
206,321
-63,562
| -24% | -$4.21M | 0.05% | 174 |
|
|
2020
Q1 | $12M | Buy |
269,883
+141,974
| +111% | +$7.37M | 0.05% | 174 |
|
|
2019
Q4 | $5.46M | Buy |
127,909
+7,645
| +6% | +$315K | 0.02% | 225 |
|
|
2019
Q3 | $5.14M | Sell |
120,264
-2,340
| -2% | -$127K | 0.02% | 218 |
|
|
2019
Q2 | $7.79M | Sell |
122,604
-55,404
| -31% | -$3.53M | 0.03% | 194 |
|
|
2019
Q1 | $12.3M | Sell |
178,008
-21,507
| -11% | -$1.23M | 0.05% | 180 |
|
|
2018
Q4 | $8.68M | Sell |
199,515
-21,206
| -10% | -$1.16M | 0.04% | 183 |
|
|
2018
Q3 | $16.9M | Sell |
220,721
-13,194
| -6% | -$1.07M | 0.06% | 168 |
|
|
2018
Q2 | $18M | Sell |
233,915
-105,330
| -31% | -$6.8M | 0.08% | 156 |
|
|
2018
Q1 | $17.3M | Sell |
339,245
-49,991
| -13% | -$2.52M | 0.08% | 156 |
|
|
2017
Q4 | $18.1M | Buy |
389,236
+22,168
| +6% | +$1.09M | 0.08% | 148 |
|
|
2017
Q3 | $19.6M | Buy |
367,068
+29,953
| +9% | +$1.77M | 0.09% | 143 |
|
|
2017
Q2 | $20.9M | Buy |
337,115
+87,777
| +35% | +$5.29M | 0.1% | 133 |
|
|
2017
Q1 | $16.9M | Buy |
249,338
+156,474
| +168% | +$11.9M | 0.08% | 142 |
|
|
2016
Q4 | $6.53M | Buy |
92,864
+37,988
| +69% | +$2.7M | 0.04% | 173 |
|
|
2016
Q3 | $3.89M | Sell |
54,876
-15,531
| -22% | -$991K | 0.02% | 214 |
|
|
2016
Q2 | $3.44M | Sell |
70,407
-43,918
| -38% | -$2.84M | 0.02% | 228 |
|
|
2016
Q1 | $7.24M | Buy |
114,325
+4,321
| +4% | +$283K | 0.04% | 218 |
|
|
2015
Q4 | $12.3M | Sell |
110,004
-5,965
| -5% | -$596K | 0.06% | 161 |
|
|
2015
Q3 | $11.2M | Buy |
115,969
+29,639
| +34% | +$3.39M | 0.06% | 170 |
|
|
2015
Q2 | $8.84M | Buy |
86,330
+4,632
| +6% | +$360K | 0.04% | 240 |
|
|
2015
Q1 | $5.07M | Buy |
81,698
+6,103
| +8% | +$339K | 0.02% | 341 |
|
|
2014
Q4 | $3.32M | Buy |
+75,595
| New | +$3.46M | 0.02% | 360 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Fred Alger Management's RARE Position: Q1 2026 in Review
Fred Alger Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 28% in Q1 2026, selling an estimated $2.56M and leaving 298,032 shares worth $6.24M. The position accounts for 0.03% of the portfolio, ranked #209.
Fred Alger Management first reported a position in RARE in Q4 2014 and has held it in 46 quarters since. The position peaked at $30.3M in Q2 2023. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Fred Alger Management held 298,032 shares of Ultragenyx Pharmaceutical worth $6.24M as of Q1 2026.
- Fred Alger Management sold 113,831 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.56M.
- Ultragenyx Pharmaceutical made up 0.03% of Fred Alger Management's portfolio in Q1 2026, its #209 holding.
- Fred Alger Management first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 46 quarters since.
- Fred Alger Management's Ultragenyx Pharmaceutical position peaked at $30.3M in Q2 2023.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.